Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Zepbound should be discontinued if pregnancy is recognized
How will emerging drug delivery innovations reshape patient outcomes in rare endocrine therapies
GLP-1 agonists are not cost-effective compared to gastric bypass for patients with severe obesity if current drug pricing persists, with an incremental cost-effectiveness ratio exceeding $500,000 per QALY over 10 years
MedicalNewsToday, Sissons, B
Although they are underdeveloped compared with nanomedicines for diseases such as cancer, findings from preclinical studies suggest that renal nanomedicines may hold promise
Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB
US$ 22.52
US$ 27.46
US$ 27.31
US$ 26.58
US$ 27.21
US$ 21.71
US$ 24.71
US$ 23.79
US$ 28.77
US$ 28.29
